Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485008 | 0.86 | P2RX7 (0.45) | TEAD1P2RX7CXCR4PDCD1LG2CD274 | |
| SCHEMBL4635783 | 0.78 | TEAD1 (0.51) | TEAD1BCHEACHEBACE1SIGMAR1 | |
| SCHEMBL5437369 | 0.77 | SIGMAR1 (0.44) | TEAD1PDCD1LG2CD274BCHEACHE | |
| SCHEMBL5994005 | 0.76 | STS (0.54) | PDCD1LG2CD274 | |
| SCHEMBL4485246 | 0.74 | BCHE (0.43) | TEAD1PDCD1LG2CD274BCHEACHE | |
| SCHEMBL64531 | 0.72 | GLA (0.56) | P2RX7CXCR4 | |
| SCHEMBL6186246 | 0.72 | CXCR4 (0.43) | P2RX7CXCR4BCHEACHEBACE1 | |
| SCHEMBL4687118 | 0.72 | SCN9A (0.47) | P2RX7 | |
| SCHEMBL6112140 | 0.72 | SCN9A (0.47) | P2RX7 | |
| SCHEMBL4634797 | 0.71 | PDK2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306123-A1 | NOVEL COMPOUNDS | PFIZER INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306123-A1 | NOVEL COMPOUNDS | PFIZER INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306123-A1 | NOVEL COMPOUNDS | PFIZER INC. (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1638933-B1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2008-06-11 | — | — | EP | disclosed |
| EP-1638933-B1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2008-06-11 | — | — | EP | disclosed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | AOC3, ADRB3, HTR3C | TEAD1 3206/4885P2RX7 873/4885CXCR4 657/4885 |
| US-20080306123-A1 | NOVEL COMPOUNDS | ADRB3, HTR3A, HTR3C | TEAD1 2420/4885P2RX7 1426/4885CXCR4 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.